“navitoclax”.

“navitoclax”.

Navitoclax is an experimental drug that helps trigger self-destruction in certain cells by blocking proteins those cells use to stay alive. It works by inhibiting members of the BCL-2 family, which are proteins that normally protect cells from a process called apoptosis, or programmed cell death. By turning off those protective proteins, navitoclax makes damaged, diseased, or unwanted cells more likely to die on their own. Researchers developed it originally to fight cancers that rely on these survival proteins, and it has been tested in clinical trials for several types of blood and solid tumors. In addition to cancer, navitoclax can selectively clear out old, non-dividing cells that accumulate with age and cause inflammation and tissue dysfunction. Removing those senescent cells has shown promise in animal studies for improving organ function and slowing aspects of aging, which is why scientists are excited about its potential beyond oncology. However, the drug can cause significant side effects, most notably a drop in platelet counts that raises the risk of bleeding, because platelets also depend on the same survival proteins. Because of these risks, researchers are exploring lower doses, intermittent schedules, targeted delivery, and drug combinations to keep benefits while reducing harm. Navitoclax matters because it represents a way to directly remove harmful cells rather than just treat symptoms, offering a potential route to better cancer therapies and treatments for age-related diseases if safety challenges can be managed.